Education & Training

Notable Recent Papers

Notable recent papers in the field are highlighted below.

The NCRI AML18 trial: CPX-351 vs DA_Mylotarg in non-adverse risk AML (Knapper et al 2026)

Latest international update for how to use MRD in clinical practice, developed by members of the ELN-DAVID MRD Working Party, including recommendations for ultra-high sensitivity FLT3 NGS MRD testing (Cloos et al 2025)

Treatment intensification with DA-Cladribine or FLAG-Ida for residual disease: AML18 (Russell et al 2025)

Molecular monitoring vs standard clinical care in younger older with AML: results from AML17 and AML19 (Potter et al 2025)

Molecular, clinical and therapeutic determinants of outcome in NPM1-mutated AML (Othman et al 2024)

Fractioned vs single-dose gemtuzumab in older patients with AML: AML18 (Freeman et al 2023)

The NCRI AML19 trial: CPX-351 vs FLAG-Ida in adverse karyotype AML and high-risk MDS (Othman et al 2023).

Upcoming Meetings & Opportunities for Junior Colleagues

British Society of Haematology Annual Meeting 2026, Liverpool

19-21st April 2026

Southwest Acute Leukaemia Forum, Taunton

This meeting will provide South West delegates with a useful opportunity to share latest data, best practice and keep up to date with changes in Acute Leukaemia practice.

13th May 2026

Northern Myeloid Day, York

National expert speakers will deliver updates on acute myeloid leukaemia and myeloproliferative neoplasms.

3rd July 2026

AML Academy 2026, Birmingham

Yearly expert-led update on state of-the-art management of adult AML

17th-18th September 2026 TBC

AML Bites Journal Club Program

Coming soon; a national discussion group for review of the most interesting recent papers in the field.